FDC Profit & Loss Annual

BSE: 531599 | NSE: FDC | ISIN: INE258B01022 | Sector: Biotechnology & Drugs

495.15 +6.25 (1.28%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	1,942.94	1,783.75	1,527.92	1,333.20
Total Revenue	1,942.94	1,783.75	1,527.92	1,333.20
Costof Revenue Total	656.15	747.12	600.46	467.92
Gross Profit	1,286.79	1,036.63	927.46	865.29
Selling/ General/ Admin Expenses Total	413.40	751.53	642.69	486.56
Depreciation/ Amortization	39.92	38.94	37.30	37.81
Other Operating Expenses Total	534.85	17.03	15.24	31.42
Total Operating Expense	1,644.32	1,571.72	1,311.53	1,039.09
Operating Income	298.62	212.04	216.38	294.12
Interest Inc( Exp) Net- Non- Op Total	-40.34	438.74	654.25	890.82
Other Net	101.63	0.99	6.58	3.85
Net Income Before Taxes	396.22	257.80	289.39	387.73
Provisionfor Income Taxes	91.16	63.98	73.23	86.53
Net Income After Taxes	305.06	193.83	216.16	301.20
Minority Interest	0.16	0.21	0.24	0.15
Net Income Before Extra Items	305.22	194.04	216.40	301.35
Net Income	305.22	194.04	216.40	301.35
Income Availableto Com Excl Extra Ord	305.22	194.04	216.40	301.35
Income Availableto Com Incl Extra Ord	305.22	194.04	216.40	301.35
Diluted Net Income	305.22	194.04	216.40	301.35
Diluted Weighted Average Shares	16.43	16.62	16.88	17.00
Diluted EPS Excluding Extra Ord Items	18.58	11.67	12.82	17.73
Diluted Normalized EPS	18.58	11.63	12.78	17.79
Research Development	-	170.98	158.48	132.58
Gain( Loss)on Saleof Assets	-	9.05	9.97	6.77
Unusual Expense( Income)	-	-	0.00	2.13